中樞神經基因及細胞治療研發中心

主持人:邱琮朗/Tsung-Lang Chiu

聯絡資訊: TEL 03-856-1825#12425
E-mail:Email住址會使用灌水程式保護機制。你需要啟動Javascript才能觀看它
                                                                                              

 

 

  

現職:花蓮慈濟醫院神經醫學科學中心主任、神經外科主治醫師
學歷:慈濟大學醫學研究所博士
研究興趣/研究主題/研究方向/專長:神經腫瘤學、腦血管疾病、基因治療、腫瘤幹細胞科腫瘤
研究領域:癌症遺傳與表觀遺傳癌症與幹細胞發育人類乳突病毒與子宮頸癌、卵巢癌         

 

近期著作發表:

  1. Chin Cheng Su*, Chiu Tsung Lang. Sann-Joong-Kuey-Jian-Tang can increase the expression levels of TNF-α, Fas, FADD,Caspase-8, -9 and -3 but decrease Bcl-xL, MCL-1 and TCTP in human hepatocellular carcinoma J5 cells xenograft tumor. Sylwan. 2016; 160(11): 190-211.
  2. CHIN-CHENG SU, CHIU TSUNG-LANG. Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo. ONCOLOGY REPORTS. 2016; 36(2): 1173-1179.
  3. Jen-Hung Fang, Tsung-Lang Chiu, Wei-Chen Huang, Yen-Ho Lai, Shang-Hsiu Hu, You-Yin Chen, Chen* San-Yuan. Dual-Targeting Lactoferrin-Conjugated Polymerized Magnetic Polydiacetylene-Assembled Nanocarriers with Self-Responsive FluorescenceMagnetic Resonance Imaging for In Vivo Brain Tumor Therapy. Advanced Healthcare Materials. 2016; 5(6): 688-695.
  4. Kuan-Pin Chen, Yu-Cheng Chou, Chia-Fone Lee , Tomor Harnod, Shin-Yuan Chen , Chain-Fa Su, Peir-Rong Chen, Tsung-Lang Chou*. Prognostic factors of paranasal sinusitis with intracranial invasion: A 14-year review of cases at Hualien Buddhist Tzu Chi Hospital. Tzu Chi Medical Journal. 2016; 28(1): 24-26.
  5. TSUNG-LANG CHIU, SU* CHIN-CHENG. SANN- JOONG-KUEY -JIAN –TANG inhibits the migration of human glioblastoma DBTRG cells through decreasing the protein expressions of nuclear factor kappa B (NF-κB), cyclooxygenase 2 (COX 2) and matrix metalloproteinase-2, 7, 9 expression. Sylwan. 2016; 160(6): 231-256.
  6. Chain-Fa Su, Dai-Wei Liu, Cheng-Chia Lee, Chiu. Tsung-Lang. Volume-staged gamma knife surgery for the treatment of large skull base meningioma surrounding the optical apparatus: A snowman-shape design. Journal of the Chinese Medical Association. 2017; 80(11): 697-704
  7. Chiu Sheng-Chun, Chiu Tsung-Lang, Huang Sung-Ying, Chang Shu-Fang, Chen Shee-Ping, Pang Cheng-Yoong, Hsieh Teng-Fu. Potential therapeutic effects of N-butylidenephthalide from Radix Angelica Sinensis (Danggui) in human bladder cancer cells. BMC Complementary and Alternative Medicine. 2017; 17(1): 523.
  8. Chiu T. L., Su C. C. Tanshinone IIA increases protein expression levels of PERK, ATF6, IRE1alpha, CHOP, caspase3 and caspase12 in pancreatic cancer BxPC3 cellderived xenograft tumors. Mol Med Rep. 2017; 15(5): 3259-3263.
  9. Guan‑Chyuan Wang, Kuan‑Pin Chen , Chain‑Fa Su, Yen‑Ta Huang, TsungLang. Neurosurgery for sinusitis-related and sinusitis-unrelated intracranial abscess. Formosan Journal of Surgery. 2017; 50(2): 63-68.
  10. Guan-Chyuan Wang , Kuan-Pin Chen , Tsung-Lang Chiu, Su Chain-Fa. 55_Treating intracranial dural arteriovenous fistulas with gamma knife radiosurgery: A single-center experience. Tzu Chi Medical Journal. 2017; 29(1): 18-23
  11. Guan-Chyuan Wang, Tomor Harnod, Tsung-Lang Chou, Chen* Kuan-Pin. Effect of an Anterior Cingulotomy on Pain, Cognition, and Sensory Pathways. World Neurosurgery. 2017; 120: 593-597.
  12. Kuan-Pin Chen, Cheng-Chia Lee, Chia-Lin Liao, Tao-Chieh Yang, Tsung-Lang Chiu, Su. Chain-Fa. Upfront Gamma Knife Surgery for Giant Central Neurocytoma. World Neurosurgery. 2017; 97: 751.e715–751.e721.
  13. Chien‑Hui Lee, Sheng‑Tzung Tsai, Chiu TsungLang*. Superficial temporal artery-middle cerebral artery bypass for the treatment of complex middle cerebral artery aneurysms. Tzu Chi Med J. 2018; 30(2): 110-115.
  14. Liao KF, Chiu TL, Huang SY, Hsieh TF, Chang SF, Ruan JW, Chen SP, Pang CY, SC*. Chiu. Anti-Cancer Effects of Radix Angelica Sinensis (Danggui) and N-Butylidenephthalide on Gastric Cancer: Implications for REDD1 Activation and mTOR Inhibition. Cell Physiol Biochem. 2018; 48(6): 2231-2246.

完整著作連結請點此

 

執行計畫(包含產學合作計畫)

補助/委託機構

計畫名稱

起迄日期

長弘生物科技股份有限公司

一個 第 I/IIa期 臨床 試 驗,針對高度 惡性神經 膠質瘤復發且合併帝盟多膠 囊(Temozolomide)治療的病患,給予 Cerebraca wafer後決定其最大耐受劑量並評估其安全性與有效性。 (共同主持人)

2017.10.01 ~  2021.12.31

國璽幹細胞應用技術股份有限公司

以自體脂肪幹細胞(ADSC)腦部移植治療陳舊性腦中風病人之phase I人體試驗研究

 (共同主持人)

 

2018.06.01~2019.12.31

鈦隼生物科技股份有限公司

NaoTrac 導航手術機器人準確度評估

2018.06.01~2019.12.31

國璽幹細胞應用技術股份有限公司

一項開放標記的第二期臨床試驗,評估GXNPC-1 (自體脂肪衍生幹細胞)用於慢性中風患者之療效和安全性

2019.06.01~2021.12.31

鈦隼生物科技股份有限公司

手術導航機器人進行腦部活體組織切片之安全、有效與可用性評估

2020.09.15~2021.09.15

 

相關學會會員資格:

  1. 台灣外科醫學會
  2. 台灣外科醫學會腫瘤外科專科指導醫師
  3. 社團法人台灣神經外科醫學會
  4. 台灣神經腫瘤醫學會